title: Kidney retransplantation in the cyclosporine era.
abstract: The results of kidney retransplantation in the cyclosporine era remain to be determined. Over a 42-month period, 76 nonprimary renal transplants (66 second, 7 third, 3 fourth allografts) were performed in 73 recipients under cyclosporine immunosuppression. The patient population was predominantly white (90.4%) with a mean age of 32.3 years. Twenty-one recipients (28.8%) were diabetic, and 36 (49.3%) were highly sensitized (panel-reactive antibody [PRA] greater than 50%). Sixty-two patients received cadaver donor grafts while the remaining donations were living-related (12) or living-unrelated (2). A sequential antilymphocyte globulin/cyclosporine protocol was employed, with cyclosporine therapy delayed until adequate renal function occurred. Overall patient and graft survival is 92.1% and 60.5%, respectively, after a mean follow-up of 20.0 months. The mean serum creatinine is 1.64 mg/dl in the 46 functioning allografts. Graft survival is 63.6% for secondary grafts, 28.6% for tertiary grafts, and 66.7% for fourth kidney transplants. In second transplants, recipients of cadaver donor kidneys have a graft survival of 58.5%, while living-related donor graft survival is 84.6% (P = 0.07). In the cadaver retransplant population, duration of previous transplant function greater than one year and HLA-DR matching were associated with increased graft survival, while age over 39 and presence of diabetes mellitus with reduced graft survival. However, these trends were not significant. Peak PRA above 50% did demonstrate a significant negative impact on graft survival both in the univariate and multivariate analyses of risk factors. Acute rejection occurred in 50 patients (65.8%), and was successfully reversed 50% of the time. Of the 30 grafts lost, 25 (83.3%) occurred within four months of retransplantation. Transplant nephrectomy was performed in 20 patients. Cyclosporine was not administered in 21 (70%) of these early graft failures, negating any potential beneficial effect. Retransplantation can be performed safely, with living-donor graft survival superior to cadaver retransplant rates. Rejection and early graft loss are common, especially in the highly sensitized patient. The impact of cyclosporine immunosuppression in renal retransplantation is much less dramatic than in primary transplantation in a protocol that delays cyclosporine therapy until allograft function is demonstrated.
authors.affiliation: Department of Surgery, University of Wisconsin School of Medicine, Madison 53792.
authors.forename: R J
authors.initials: RJ
authors.lastname: Stratta
authors.forename: C S
authors.initials: CS
authors.lastname: Oh
authors.forename: H W
authors.initials: HW
authors.lastname: Sollinger
authors.forename: J D
authors.initials: JD
authors.lastname: Pirsch
authors.forename: M
authors.initials: M
authors.lastname: Kalayoglu
authors.forename: F O
authors.initials: FO
authors.lastname: Belzer
mesh_terms: D001803:Blood Transfusion; D002102:Cadaver; D003524:Cyclosporins / Q000627:therapeutic use*; D006085:Graft Survival; D006801:Humans; D016030:Kidney Transplantation; D012086:Reoperation; D012189:Retrospective Studies; D014019:Tissue Donors
chemical_list: D003524:Cyclosporins